Loading...
XNAS
MNKD
Market cap1.09bUSD
Oct 08, Last price  
3.42USD
1D
-0.87%
1Q
-16.38%
Jan 2017
7.43%
IPO
-95.12%
Name

MannKind Corp

Chart & performance

D1W1MN
XNAS:MNKD chart
P/E
186.31
P/S
3.13
EPS
0.02
Div yield, %
—
Shrs. gr., 5y
7.13%
Rev. gr., 5y
39.89%
Revenues
349m
+22.23%
100,00010,00020,000093,00050,00035,000000174,758,00011,745,00027,859,00063,038,00065,144,00075,442,00099,770,000198,962,000285,504,000348,966,000
Net income
6m
-78.75%
-230,548,000-293,190,000-303,039,000-220,104,000-170,560,000-160,804,000-169,366,000-191,490,000-198,382,000-368,445,000125,664,000-117,333,000-86,975,000-51,903,000-57,240,000-80,926,000-87,400,000-11,938,00027,588,0005,863,000
CFO
18m
-57.06%
-189,794,000-245,146,000-271,288,000-184,083,000-148,654,000-123,837,000-119,860,000-128,732,0004,086,000-57,232,000-78,090,000-64,778,000-37,731,000-88,483,000-28,128,000-61,709,000-80,697,00034,094,00042,511,00018,255,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.

Key people

James Shannon
Independent Chairman of the Board · since 2020
Michael Castagna
Chief Executive Officer, Director · since 2017
Christopher Prentiss
Chief Financial Officer · since 2024
Dominic Marasco
President, Endocrine Business Unit · since 2025
Burkhard Blank
Executive Vice President - Research & Development, Chief Medical Officer · since 2023
Sanjay Singh
Executive Vice President - Technical Operations · since 2022
Stuart Tross
Executive Vice President, Chief People and Workplace Officer · since 2021
David Thomson
Executive Vice President, General Counsel, Secretary · since 2002
Steven Binder
Director · since 2024
Ronald Consiglio
Independent Director · since 2003
Michael Friedman
Independent Director · since 2003
Jennifer Grancio
Independent Director · since 2020
Anthony Hooper
Independent Director · since 2020
Christine Mundkur
Independent Director · since 2018
URL
https://mannkindcorp.com/
IPO date
Jul 28, 2004
Employees
391
Domiciled in
US
Incorporated in
US
Legal address
CORPORATION SERVICE COMPANY
2711 CENTERVILLE RD SUITE 400
WILMINGTON, DE 19808
US
Headquarters
28903 NORTH AVENUE PAINE
VALENCIA, CA 91355
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT